Monsanto's arthritis drug sells briskly

Article Abstract:

Second only to Viagra, Monsanto's Celebrex generated the writing of 82,600 prescriptions in its third week on the market for treatment of arthritis pain. Pfizer, maker of Viagra, is co-marketing Celebrex, but the two drug companies haven't even begun to sell formally as yet. Sales thus far are a result of the success of the 30-day free trial packs that doctors received. It's popularity may be due in large part to Celebrex's more gentle effect on the stomach and for not causing bleeding ulcers. Its effect on pain isn't much different from current medications.

Comment:

Company has second-best selling drug, Celebrex

Sales & consumption, Supply and demand, Statistics, Drug therapy, Palliative treatment, Palliative care, Arthritis

---

Monsanto drug could ignite marketing war; drug approved by FDA to treat arthritis pain may not cause ulcers

Article Abstract:

Monsanto Co. has the FDA's approval to market Celebrex but the drug's label must still warn about the possible side effects like bleeding ulcers. Consequently, the firm has kept pricing in line with current drug treatments on the market for rheumatoid arthritis. This requirement is disappointing to the firm and says it will also effect it's marketing efforts aimed directly at consumers.

Comment:

FDA's approval of Celebrex still limits company's labeling

Marketing procedures, New Products/Services, Care and treatment, Marketing, Investigations, Rheumatoid arthritis, United States. Food and Drug Administration

---

Similar abstracts:

• Abstracts: Abbott acquires co-marketing rights to arthritis drug. Monsanto arthritis-pain drug, Celebrex, surpasses Viagra's early sales success
• Abstracts: FDA approves a new drug for arthritis. Monsanto's arthritis drug, Celebrex, shows strong sales in its first week
• Abstracts: IBM targets Sun with guerrilla tactics. Two GM divisions try to create different images for their trucks

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.